Adial Pharmaceuticals
ADIL
15 hedge funds and large institutions have $63.8K invested in Adial Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 11 closing their positions.
1.96% more ownership
Funds ownership: 0.53% → 2.5% (+2%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
32% less funds holding
Funds holding: 22 → 15 (-7)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
92% less capital invested
Capital invested by funds: $778K → $63.8K (-$715K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$63.4K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.58K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$615 |
| 4 |
Morgan Stanley
New York
|
+$176 |
| 5 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$53 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$562K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$48.3K |
| 3 |
Jane Street
New York
|
-$26.8K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$14.5K |
| 5 |
VF
Virtu Financial
New York
|
-$14K |
ADIL Hedge Fund Activity: Q1 2026 in Review
15 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q1 2026, worth a combined $63.8K — down 92% from $778K a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ADIL and 5 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Geode Capital Management, adding an estimated $63.4K. The largest seller was Armistice Capital, exiting entirely with an estimated $562K sold.
- 15 institutional investors held Adial Pharmaceuticals (ADIL) as of Q1 2026, down from 22 in Q4 2025.
- Funds reported $63.8K of Adial Pharmaceuticals stock for Q1 2026, down 92% quarter-over-quarter.
- 5 funds opened new Adial Pharmaceuticals positions in Q1 2026 and 11 closed out, a net change of -6 holders.
- The largest Adial Pharmaceuticals buyer in Q1 2026 was Geode Capital Management, an estimated $63.4K added.
- The largest Adial Pharmaceuticals seller in Q1 2026 was Armistice Capital, an estimated $562K sold.
Based on aggregated 13F filings for Q1 2026.